IRCT20210710051831N1招募中2 期
Comparison assessment of Bosentan and routine medication on pulmonary hypertension among hospitalized patients with COVID-19
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients with COVID-19 referred to Boali Sina hospital, Qazvin during 1400
- •patients with COVID-19 pneumonia and pulmonary hypertension
- •Willingness to participate in a research project
- •Signing the informed consent form
排除标准
- •Age range under 14 years
- •Pregnant women
- •History of pulmonary hypertension
- •Severe obstructive pulmonary disease
研究者
相似试验
已完成
3 期
Bosentan for high-risk outpatients with COVID-19IRCT20211203053263N1Ilam University of Medical Sciences350
已完成
3 期
Bosentan in hospitalized patients with COVID-19 infectioCOVID-19.COVID-19, virus identifiedU07.1IRCT20211203053263N2Ilam University of Medical Sciences200
进行中（未招募）
不适用
Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSACProgressive pulmonary sarcoidosisMedDRA version: 9.1Level: PTClassification code 10037430Term: Pulmonary sarcoidosisEUCTR2007-005117-18-ATMedical University of Vienna, Department of Clinical Pharmacology
已完成
不适用
Bosentan improves clinical Outcome of adults with congenital heart disease or mitral valve lesions who undergo CArdiac surgeryaangeboren hartafwijkingopen hart operatie risico1004697310007510NL-OMON36241Academisch Medisch Centrum110
已完成
不适用
Study on the effect of Bosentan on trophic skin lesions in diabetic fOOT Syndrome (BOOTS)Diabetic foot syndromeNutritional, Metabolic, EndocrineInsulin-dependent diabetes mellitusISRCTN51795022niversity Hospital Zürich (Switzerland)20